Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Merck
Mallinckrodt
Harvard Business School
McKesson

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,410,550

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,410,550 protect, and when does it expire?

Patent 6,410,550 protects CHANTIX and is included in one NDA.

Protection for CHANTIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and twenty-two patent family members in fifty-four countries.

Summary for Patent: 6,410,550
Title: Aryl fused azapolycyclic compounds
Abstract:Compounds of the formula ##STR1## and their pharmaceutically acceptable salts, wherein R.sup.1, R.sup.2, and R.sup.3 are defined as in the specification, intermediates in the synthesis of such compounds. pharmaceutical compositions containing such compounds and methods of using such compounds, in the treatment of neurological and psychological disorders.
Inventor(s): Coe; Jotham Wadsworth (Niantic, CT), Brooks; Paige Roanne Palmer (North Stonington, CT)
Assignee: Pfizer INC (New York, NY)
Application Number:09/402,010
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,410,550

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928-001 May 10, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928-002 May 10, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,410,550

PCT Information
PCT FiledNovember 13, 1998PCT Application Number:PCT/IB98/01813
PCT Publication Date:July 15, 1999PCT Publication Number: WO99/35131

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Dow
AstraZeneca
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.